THRYClinical Trials•prnewswire•August 25, 2025 at 03:38 PM

Thryv Therapeutics to Present at the 2025 European Society of Cardiology Congress in Madrid, Spain

Sentiment:Negative (30)

Summary

MONTREAL, Aug. 25, 2025 /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company, today announced that Dr. Saumya Das will present compelling new preclinical results on its lead compound, THRV-1268, at the upcoming European Society of Cardiology (ESC) Congress 2025,...

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 25, 2025 by prnewswire